RPG Life Sciences has executed a Business Transfer Agreement to slump sale its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), for ₹33.55 crore. The transaction, approved by the Board on July 29, 2026, aims to create a focused API entity with dedicated capital, while the parent company concentrates on its formulations business. This strategic restructuring positions the API segment to attract external investment and pursue aggressive growth in a structurally realigning global supply chain.

The sale consideration of ₹33.55 crore is subject to adjustments based on actual assets and liabilities at closing, expected by September 30, 2026. Concurrently, RPGAP has entered into an investment agreement with InvAscent, a healthcare-focused private equity firm. Funds managed by InvAscent will make an initial investment of up to ₹243 crore in RPGAP. The parties have committed to infusing an aggregate amount of up to ₹700 crore in tranches to fund organic and inorganic growth, including manufacturing expansion and product portfolio enhancement.

Financial Impact and Rationale

The API business contributed ₹95.06 crore to revenue in FY26, representing 13.54% of consolidated turnover. Its net worth stood at ₹70.92 crore as of March 31, 2026. Management stated that the spin-off allows sharper focus on API growth within the subsidiary structure. Ashok Nair, Managing Director of RPG Life Sciences, noted that the partnership with InvAscent brings 20 years of pharma investing experience to complement the company’s execution track record.

Investment and Acquisition Strategy

RPGAP has also executed a Share Purchase Agreement to acquire 100% of Actis Generics Private Limited (Actis), an API manufacturer based in Visakhapatnam. The acquisition cost is ₹80 crore, subject to working capital adjustments, with completion targeted by November 15, 2026. Actis reported a turnover of ₹48.24 crore in FY25. Dr. Jeevak Gupta, Managing Director of InvAscent, stated that the investment supports building a differentiated API business with long-term growth potential.

What the Numbers Show

The restructuring highlights a divergence between the internal transfer price and market valuation. While the slump sale consideration was ₹33.55 crore against a net worth of ₹70.92 crore, the initial ₹243 crore investment by InvAscent implies a significantly higher valuation for the subsidiary. This structure leverages the spin-off to attract specialized capital for expansion, including the acquisition of key supply chain partners like Actis Generics.

Regulatory Disclosures

The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The transaction falls outside the Scheme of Arrangement and does not constitute the sale of substantially the whole undertaking under Section 180 of the Companies Act, 2013. Khaitan & Co. acted as legal counsel, o3 Capital as financial advisor, Quillon Partners as legal counsel for the acquisition, and Deloitte undertook financial due diligence.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE105J01010/f3ce612a-263a-4c03-bbbe-ce8637e31e13.pdf

RPG Life Sciences Limited reported a 15.8% year-on-year increase in consolidated revenue from operations to ₹195.7 crore for the quarter ended June 30, 2026 (Q1FY27), driven by robust domestic formulation sales and a significant recovery in its API segment. Consolidated profit after tax (PAT) rose 17.0% to ₹30.8 crore from ₹26.3 crore in the prior year period, while EBITDA expanded 17.9% to ₹48.0 crore with margins improving to 24.5% from 24.1%. The Board of Directors approved the unaudited financial results on July 28, 2026, following review by the Audit Committee and limited review by statutory auditors S R B C & Co LLP pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subsequently published in Business Standard and Mumbai Lakshadeep on July 29, 2026.

The company’s performance was anchored by its Domestic Formulations (DF) business, which contributed 68.3% of total sales and grew 14.8% to ₹132.5 crore, outperforming the broader Indian Pharma Market growth of 11.6%. This growth was supported by key therapy focus, new product introductions in specialty and chronic segments, and improved field-force effectiveness, with productivity exceeding ₹6.5 lakh per member. International Formulations registered 7.7% growth to ₹35.0 crore, contributing 18.0% to total sales. The API business delivered a strong 35.6% growth to ₹26.6 crore as units returned to operations following a fire incident in one of the manufacturing blocks during the prior year.

Financial Performance Highlights

Consolidated revenue from operations stood at ₹195.7 crore for the quarter, up from ₹168.9 crore in Q1FY26. Profit before tax (PBT) increased 17.0% to ₹41.5 crore from ₹35.4 crore, with PBT margin expanding slightly to 21.2% from 21.0%. Finance costs remained low, supporting bottom-line expansion. No exceptional items were recorded in Q1FY27, unlike the previous fiscal year which saw impacts from insurance claims and new labour codes.

On a standalone basis, revenue came in at ₹196 crore versus ₹170 crore in the corresponding quarter of the previous year. Standalone EBITDA stood at ₹43.6 crore compared to ₹35.5 crore, with standalone EBITDA margin improving to 22.27% from 21.0%. Standalone net profit was ₹30.6 crore versus ₹26.3 crore in the prior year period. Earnings per share (basic and diluted) rose to ₹18.49 from ₹15.90 in the corresponding quarter of the previous year.

Strategic Roadmap and Market Position

RPG Life Sciences outlined a seven-pillar strategic roadmap to drive future growth, focusing on portfolio development, mega-brand building, and digital transformation. The company aims to grow its immunosuppressant portfolio to over ₹200 crore and scale core brands like Naprosyn towards becoming a ₹100 crore+ brand. Key brands such as Naprosyn grew at 16%, alongside double-digit growth in nephrology and rheumatology baskets. The company also entered the coveted list of "Top 50 Pharma Companies" in India as per the Indian Pharma Market report for June 2026, advancing its ranking from 62 in March 2025 to 50 in June 2026.

ICRA reaffirmed the long-term rating at A+ with a stable outlook, citing robust capital structure, healthy cash flows, and no debt-funded capital expenditure. The credit agency highlighted steady top-line growth and improving operating margins as key factors supporting the rating affirmation. RPG Life Sciences also received three industry awards in Q1FY27, including "Top Nephrology Company-2026" by India Pharma Outlook, recognizing its strong patient care through a robust portfolio in the kidney care space.

What the Numbers Show

The expansion in EBITDA margin despite rising operational costs indicates effective cost management and pricing power in core therapeutic areas. The divergence between domestic formulation growth (14.8%) and market growth (11.6%) highlights RPG Life Sciences' competitive advantage in its home market. The significant recovery in the API segment suggests successful operational turnaround efforts, contributing to the overall robustness of the earnings profile. With ₹185+ crore capex infused since FY22 helping build modern plants with EU, TGA, and PMDA approvals, the company is well-positioned to capitalize on global opportunities while strengthening its domestic presence.